Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results.

Saved in:
Bibliographic Details
Title: Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results.
Authors: Pidala J; Department of Blood and Marrow Transplantation - Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.; Department of Immunology, Moffitt Cancer Center, Tampa, Florida.; Department of Oncologic Sciences, University of South Florida, Tampa, Florida., Walton K; Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota., Elmariah H; Department of Blood and Marrow Transplantation - Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.; Department of Oncologic Sciences, University of South Florida, Tampa, Florida., Kim J; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida., Mishra A; Department of Blood and Marrow Transplantation - Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.; Department of Oncologic Sciences, University of South Florida, Tampa, Florida., Bejanyan N; Department of Blood and Marrow Transplantation - Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.; Department of Oncologic Sciences, University of South Florida, Tampa, Florida., Nishihori T; Department of Blood and Marrow Transplantation - Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.; Department of Oncologic Sciences, University of South Florida, Tampa, Florida., Khimani F; Department of Blood and Marrow Transplantation - Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.; Department of Oncologic Sciences, University of South Florida, Tampa, Florida., Perez L; Department of Blood and Marrow Transplantation - Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.; Department of Oncologic Sciences, University of South Florida, Tampa, Florida., Faramand RG; Department of Blood and Marrow Transplantation - Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.; Department of Oncologic Sciences, University of South Florida, Tampa, Florida., Davila ML; Department of Blood and Marrow Transplantation - Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.; Department of Immunology, Moffitt Cancer Center, Tampa, Florida.; Department of Oncologic Sciences, University of South Florida, Tampa, Florida., Nieder ML; Department of Blood and Marrow Transplantation - Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.; Department of Oncologic Sciences, University of South Florida, Tampa, Florida., Sagatys EM; Department of Hematopathology and Laboratory Medicine, Moffitt Cancer Center, Tampa, Florida., Holtan SG; Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota., Lawrence NJ; Department of Drug Discovery, Moffitt Cancer Center, Tampa, Florida., Lawrence HR; Department of Drug Discovery, Moffitt Cancer Center, Tampa, Florida., Blazar BR; Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota., Anasetti C; Department of Blood and Marrow Transplantation - Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.; Department of Immunology, Moffitt Cancer Center, Tampa, Florida.; Department of Oncologic Sciences, University of South Florida, Tampa, Florida., Sebti SM; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia., Betts BC; Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. bett0121@umn.edu.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 May 15; Vol. 27 (10), pp. 2712-2722. Date of Electronic Publication: 2021 Mar 22.
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-20-4725